Abstract: A laboratory flask for use in association with a laboratory heating block, having: a flask body, wherein the flask body includes an upper portion, a lower portion, and a sidewall, wherein the sidewall of the flask body includes an inner surface, and an outer surface; a neck, wherein the neck includes an upper portion, a lower portion, and a sidewall, wherein the sidewall of the neck includes an inner surface, and an outer surface, and wherein the neck emanates contiguously from the flask body; and a reservoir, wherein the reservoir includes an upper portion, a lower portion, a bottom wall, and a sidewall, wherein the sidewall of the reservoir includes an inner surface, and an outer surface, and wherein the reservoir is adapted for releasable securement within a laboratory heating block.

Abstract: A laboratory flask for use in association with a laboratory heating block, having: a flask body, wherein the flask body includes an upper portion, a lower portion, and a sidewall, wherein the sidewall of the flask body includes an inner surface, and an outer surface; a neck, wherein the neck includes an upper portion, a lower portion, and a sidewall, wherein the sidewall of the neck includes an inner surface, and an outer surface, and wherein the neck emanates contiguously from the flask body; and a reservoir, wherein the reservoir includes an upper portion, a lower portion, a bottom wall, and a sidewall, wherein the sidewall of the reservoir includes an inner surface, and an outer surface, and wherein the reservoir is adapted for releasable securement within a laboratory heating block.

Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.

Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.

Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.

Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.

Abstract: Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF4, SF5Cl, SF5Br and SF6. The methods described herein generally require lower temperature and pressure, produce higher yields, require less time, do not use corrosive or costly reactants and solvents that are commonly used in the synthesis of the fluoro-sulfur compounds, and do not produce deleterious waste products when compared to previously-used methods.

Abstract: Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF4, SF5Cl, SF5Br and SF6. The methods described herein generally require lower temperature and pressure, produce higher yields, require less time, do not use corrosive or costly reactants and solvents that are commonly used in the synthesis of the fluoro-sulfur compounds, and do not produce deleterious waste products when compared to previously-used methods.

Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.

Abstract: Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF4, SF5Cl, SF5Br and SF6. The methods described herein generally require lower temperature and pressure, produce higher yields, require less time, do not use corrosive or costly reactants and solvents that are commonly used in the synthesis of the fluoro-sulfur compounds, and do not produce deleterious waste products when compared to previously-used methods.

Abstract: Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF4, SF5Cl, SF5Br and SF6. The methods described herein generally require lower temperature and pressure, produce higher yields, require less time, do not use corrosive or costly reactants and solvents that are commonly used in the synthesis of the fluoro-sulfur compounds, and do not produce deleterious waste products when compared to previously-used methods.

Abstract: Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF4, SF5Cl, SF5Br and SF6. The methods described herein generally require lower temperature and pressure, produce higher yields, require less time, do not use corrosive or costly reactants and solvents that are commonly used in the synthesis of the fluoro-sulfur compounds, and do not produce deleterious waste products when compared to previously-used methods.

Abstract: Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF4, SF5Cl, SF5Br and SF6. The methods described herein generally require lower temperature and pressure, produce higher yields, require less time, do not use corrosive or costly reactants and solvents that are commonly used in the synthesis of the fluoro-sulfur compounds, and do not produce deleterious waste products when compared to previously-used methods.

Abstract: Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF4, SF5Cl, SF5Br and SF6. The methods described herein generally require lower temperature and pressure, produce higher yields, require less time, do not use corrosive or costly reactants and solvents that are commonly used in the synthesis of the fluoro-sulfur compounds, and do not produce deleterious waste products when compared to previously-used methods.

Abstract: Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF4, SF5Cl, SF5Br and SF6. The methods described herein generally require lower temperature and pressure, produce higher yields, require less time, do not use corrosive or costly reactants and solvents that are commonly used in the synthesis of the fluoro-sulfur compounds, and do not produce deleterious waste products when compared to previously-used methods.

Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.

Abstract: A method for service management for terminals with broadband connections, wherein the terminal is connected through a home gateway to a service connected in an operator network, the home gateway being attached to an access node of the operator network, includes the steps of monitoring whether the terminal is temporarily not using the service, delegating the service and transferring its current status and/or data to the access node, and tearing down the connection between the home gateway and the access node while operating the service in the delegated service host.

Abstract: A method of policing network traffic based on congestion on a flow-based programmable switch, such as an OpenFlow switch is provided. The method polices congestion-causing flows in a network by detecting congestion at a flow-based programmable switch on the network. Once congestion has been detected, the method identifies one or more flows that are causing the congestion at the flow-based programmable switch, and penalizes the flows that were identified as causing congestion. A flow-based programmable switch including a data plane having input ports, output ports, and forwarding rules that map packets received on an input port to an output port based on a packet matching a rule in the forwarding rules is also described.